The pathological and therapeutic roles of mesenchymal stem cells in preeclampsia

Sanshan Jin1,2†, Canrong Wu3†, Ming Chen4†, Dongyan Sun5 and Hua Zhang1,2*  
1Hubei University of Chinese Medicine, Wuhan, China, 2Department of Traditional Chinese Medicine, Maternal and Child Health Hospital of Hubei Province, Wuhan, China, 3The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China, 4Department of Rehabilitation Physiotherapy, Maternal and Child Health Hospital of Hubei Province, Wuhan, China, 5Department of Gynecology, Maternal and Child Health Hospital of Hubei Province, Wuhan, China

Mesenchymal stem cells (MSCs) have made progress in the treatment of ischemic and inflammatory diseases. Preeclampsia (PE) is characterized by placenta ischemic and inflammatory injury. Our paper summarized the new role of MSCs in PE pathology and its potency in PE therapy and analyzed its current limitations. Intravenously administered MSCs dominantly distributed in perinatal tissues. There may be additional advantages to using MSCs-based therapies for reproductive disorders. It will provide new ideas for future research in this field.

KEYWORDS
PE, MSCs, MSCs transplantation, exosome, pregnancy, placenta

Introduction

Preeclampsia (PE) is a leading gestational disease that harms both the mother and the fetus in the short and long term. Mesenchymal stem cells (MSCs) are coordinated in endometrial decidualization and placental development. MSCs derived from PE patients show high senescence and apoptosis rate which impair the crosstalk between MSCs and endothelium, trophoblast, and immune cells in the placenta, thereby hastening the progression of PE. Preclinical and clinical data indicate that the MSCs-based therapeutic strategy is promising to be used for ischemic and inflammatory diseases. PE is characterized by placenta ischemic and inflammatory injury. MSCs have been recently applied to PE therapy. MSCs and their derivatives can ameliorate symptoms and maternal-fetal outcomes in PE model mice by boosting cell metabolism, anti-oxidative stress, stimulating angiogenesis balance, and anti-inflammation. We have summarized the interactive mechanisms between MSCs and trophoblast under physiological and hypoxic conditions in this article for the first time. MSCs therapy may show extra benefits in PE therapy for its dominant distribution in perinatal tissue. Although intravenous injection of MSCs has shown safety in clinics so far,
additional research into the safety of their administration during pregnancy is needed. MSCs-derived exosome (Exo) might be a viable option for PE therapy.

**Mesenchymal stem cells**

Synchronized endometrium decidualization, embryo implantation, and sufficient placentation are necessary for a successful pregnancy. Although lineage hierarchy and cell fate in the placenta and decidual are not well defined so far, it is undeniable that the whole endometrium regeneration, decidualization, and placentation process are mainly driven by diverse programmed stem cell activities (trophoblast stem cells, MSCs, epithelial progenitors, endothelial progenitors, etc.). Typical MSCs give rise to endothelial and vascular smooth muscle-like cells (they all participate in forming the vascular wall) in conditional mediums and form tube-like structures in Matrigel (Figure 1). MSCs secrete free or Exo encapsulated small molecules (such as cytokines, RNA and DNA) participating in various signal transduction to surrounding cells. It is well-known that MSCs have trophic effects on surrounding cells by secreting growth factors like vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), placenta growth factor (PGF), etc. MSCs also act as atypical immune cells participating in immune modulation. Until now, it is still difficult for us to get the in situ dynamic spatio-temporal data about how the stem cells actually build the endometrium and placenta. Despite its limitation in representing how MSCs work.

**Mesenchymal stem cells in endometrium regeneration**

Mesenchymal stem cells in the endometrium have similar functions to bone marrow-derived MSCs (bm-MSCs). Endometrium MSCs (eMSCs) have specific markers like CD146+, SUSD2+ (sushi domain containing-2), and PDGFRb+ (platelet-derived growth factor receptor beta), which characterized their perivascular location and possible pericyte identity (1). Besides, stromal fibroblast in the endometrium also has some MSCs properties and multilineage differentiation potential in vitro (1). Masuda found that eMSCs can differentiate into endometrial stromal structures following xenografting under the kidney capsule in the immune-compromised mice (2). In situ transplantation of MSCs can rebuild the endometrium of women with thin endometrium and restore the embryo implantation rate of these patients (3, 4).

**Mesenchymal stem cells in decidualization**

Endometrium experiences a transient decidualization stage which confers a special micro-environment to accept the implantation of the conceptus, regulate the invasion of trophoblast, and induce immune tolerance to fetal antigen (5–7) (Figure 1). Decidualization disorder is not only related to embryo implantation failure but also other lagging pregnancy disorders like miscarriage, PE, intrauterine growth restriction (IUGR) (8, 9).

Decidual stromal cells (DSCs) are the hallmark cell of the decidualization process. Recent studies identified that DSCs precursor cells (preDSCs) and eMSCs similar to each other phenotypically (CD140b, CD146, and SUSD2) and functionally (10, 11). Progesterone and cAMP primed the decidualization process (12). Progesterone (P4) and cAMP can induce decidualization-like changes in eMSCs in vitro [eMSCs become bigger and round, lose perivascular cell markers, and express prolactin (the marker of DSCs)]. Thus, eMSCs and preDSCs were postulated to be two closely related cell types or even the identical one type (13). High levels of endometrium receptivity markers like Integrin (ITG)β1, ITGβ3, Rac1, Noggin, and Homeobox A11 (HOXA11) (14) and other genes involved in inflammation, immunomodulation, hypoxia responses, and cell communication are detected in decidual MSCs (dMSCs). These changes may furnish the decidual with a friendly environment for embryo adhesion, implantation, and placentation (1) (Figure 1). Upregulated expression of insulin-like growth factor (IGF), transforming growth factor β (TGFβ), Notch, and Hedgehog receptor signaling pathway genes suggest high self-renewal and differentiation of MSCs in decidual (1). Low levels of receptivity markers were detected in dMSCs from women with recurrent implantation failure (RIF) (14). Some functional disorders have also been detected in PE-derived dMSCs and we have discussed them intensively in the following paragraphs.

**Mesenchymal stem cells in placentation**

Mesenchymal stem cells in perinatal tissue were classified into dMSCs, amniotic membrane-derived MSCs (AM-MSCs), umbilical cord MSCs (UC-MSCs), amniotic fluid MSC (AF-MSC), and chorionic villus-derived MSCs (CV-MSCs) according to their tissue site in the placenta (Figure 2). In the early stage of pregnancy, the embryo doubles in size per week thus both trophoblasts and mesenchyme in the placenta expand at a rapid rate (15). MSCs from the early trimester placenta possess the ability to differentiate into tissue from three germ layers (16). PD-MSCs show high clone formation capacity.
In situ and bone marrow recruited MSCs to participate in endometrium/decidual and placenta development by direct differentiating into endothelial, vascular smooth muscle cells, and stromal cells to form vascular and stromal tissue de novo and promote the proliferation of preexisting vascular cells and the stromal cells to build the vascular network and stromal in tissue. Progesterone/cAMP induces decidual stromal cell (DSCs) like changes in MSCs and expresses high levels of receptive markers which may promote blastocyte adhesion, implantation, and fetal antigen tolerance. MSCs secret multiple cytokines to promote proliferation and invasion of trophoblast (TB) which may foster villous expansion and maternal spinal arterial remodeling. En, Endometrium; De, Decidual; Ecs, Endothelial cells; VSMCs, Vascular smooth muscle cells; S/FCs, Stromal/fibroblast cells; V, Vascular; VN, Vascular network; SM, Stromal matrix; STB, Syncytiotrophoblast; EVTB, Extravillous trophoblast.

MSCs in endometrium/decidual and placenta development

In situ and bone marrow recruited MSCs participate in endometrium/decidual and placenta development by direct differentiating into endothelial, vascular smooth muscle cells, and stromal cells to form vascular and stromal tissue de novo and promote the proliferation of preexisting vascular cells and the stromal cells to build the vascular network and stromal in tissue. Progesterone/cAMP induces decidual stromal cell (DSCs) like changes in MSCs and expresses high levels of receptive markers which may promote blastocyte adhesion, implantation, and fetal antigen tolerance. MSCs secret multiple cytokines to promote proliferation and invasion of trophoblast (TB) which may foster villous expansion and maternal spinal arterial remodeling. En, Endometrium; De, Decidual; Ecs, Endothelial cells; VSMCs, Vascular smooth muscle cells; S/FCs, Stromal/fibroblast cells; V, Vascular; VN, Vascular network; SM, Stromal matrix; STB, Syncytiotrophoblast; EVTB, Extravillous trophoblast.

MSCs distribution in the reproductive tract and placenta

MSCs distribution in the reproductive tract and placenta. eMSCs, Endometrium MSCs; dMSCs, decidual MSCs; AM-MSCs, Amniotic membrane-derived MSCs; UC-MSCs, Umbilical cord MSCs; AF-MSC, Amniotic fluid MSC; CV-MSCs, Chorionic villus-derived MSCs.

and pro-angiogenesis potency (17). In vitro co-cultivation system, PD-MSCs foster the functions of the trophoblast and educate immune cells in the placenta (mentioned later). Reshef Ta had discerned a small population of bm-MSCs in mice placenta, they express progesterone receptor (PR), a hallmark of decidualized stromal cells (7). Hoxa11 deficiency leads to pregnancy loss in mice (18). In the bone marrow, Hoxa11 does not express in hematopoietic cells but bm-MSCs (19). Transplantation of bone marrow from Hoxa11+/+ mice can favor embryo implantation and rescue pregnancy loss in Hoxa11−/− mice (7). Maria Diniz-da-Costa characterized a transient group of highly proliferative bone marrow-derived MSCs (hPMC) in the implantation window in women's endometrium, loss of hPMC was detected in women with...
recurrent pregnancy loss (20). It posits that bm-MSCs recruited to the decidual and placenta may participate in maintaining a normal pregnancy.

**Preeclampsia**

Preeclampsia is a disease that affects approximately 5–7% of pregnancies (21, 22). PE is a multifactorial and multiorgan syndrome leading to maternal and neonatal morbidity. PE is characterized by proteinuria and hypertension and often occurs after 20 weeks of gestation (23). By now, the etiology and pathogenesis of PE are gradually elucidated (24). After embryo implantation, ectodermal cells differentiate into trophoblast cells and invade maternal uterine tissue, transform maternal uterine blood vessels, and form a stable maternal-fetal blood supply network, the placenta. The placenta is a highly vascularized temporary organ responsible for nutrients and metabolic waste exchange between mother and fetal through the placenta blood supply. Superficial trophoblast invasion, insufficient placenta formation, or other factors affecting local blood vessels of the placenta will lead to impaired placental blood perfusion, resulting in placental and fetal hypoxia/ischemia injury.

Hypoxia/ischemia related mitochondrial dysfunction (25), endoplasmic reticulum stress (26), autophagy/mitophagy disorder induce tissue oxidative injury, and finally cell apoptosis or pyroptosis in the placenta (27). High level of damage-associated molecular patterns (DAMPs) (28), pro-inflammatory cytokines, combined with increased level of anti-angiogenic factors [soluble endoglin, soluble FMS-like tyrosine kinase-1 (sFlt-1)] (29, 30) release from the injured placenta into circulation to provoke local and systematic inflammation and endothelial dysfunction (24, 31, 32). Multiple systems are implicated in PE thus it manifests as hypertension, proteinuria, retinal edema, liver and kidney dysfunction, or even life-threatening HELLP syndrome (33).

**Mesenchymal stem cells dysfunction in preeclampsia**

Recent studies have found that MSCs dysfunction is associated with the pathogenesis of PE. Human UC-MSCs (hUC-MSCs) obtained from PE women showed elevated ROS levels, decreased telomerase activity, and elevated expression of senescence-related genes (DEGs) (24, 34). JunB and Cyclin-D1 are key cell cycle-related modulators. JunB/Cyclin D1 imbalance in PE placenta-derived MSCs (PD-MSCs) can block the G1/S cell cycle transition resulting in cell senescence and reduced proliferation (35, 36). MSCs dysfunction may impair the self-proliferation and differentiation of MSCs in the PE placenta and also its crosstalk with trophoblast cells, immune cells, and endothelial cells (37–39), which may further speed up the progression of PE. Although it is not clear whether decidual/placenta MSCs dysfunction is the cause or the sequence of PE, MSCs dysfunction may promote the vicious cycle of PE.

Oxidative stress injury and inflammatory condition of the placenta may be partly responsible for impaired MSCs function in PE patients. Though moderate hypoxia can stimulate MSCs to resist oxidative stress injury, and promote angiogenesis and its self-renewal (40, 41), intensive hypoxia can lead to MSCs senescence and apoptosis (42). In addition, as inflammatory factors excite the immunomodulatory traits of MSCs, they also trigger the apoptosis of MSCs (43, 44). A variety of miRNAs and long non-coding RNAs (lncRNAs) abnormally expressed in PE patients mediate MSCs dysfunction (45, 46). These RNAs regulate genes involved in cell proliferation, senescence, apoptosis, immune/inflammation modulation, and the angiogenesis process of MSCs (47) (Table 1). Heme oxygenase 1 (HMOX1) is a multifunctional stress-response protein and plays anti-oxidant (48–50), anti-apoptosis, and anti-inflammation roles in tissues (51). HMOX1 remains at a high level throughout gestation, but Basmael Y. found HMOX1 decreased in one subtype of PD-MSCs in PE patients. H2O2 preconditioning upregulate HMOX1 expression and restore the function of PD-MSCs, but is nullified by tin protoporphyrin, an HMOX1 selective inhibitor (37). HMOX1 deficiency may be partly responsible for PD-MSCs dysfunction in PE patients. TNF-α is a pro-inflammatory cytokine elevated in PE. TNF-α induces a senescent phenotype of adipose-derived MSCs (adMSCs) with strong staining for senescence-associated components (52). Dasatinib, a senolytic agent, significantly rescues senescence and restores the proliferation and angiogenesis potency of adMSCs from PE patients (52, 53). Compared to the normal placenta, PE-derived PD-MSCs secrete higher levels of pro-inflammatory cytokines like IL-8, IL-6, migration inhibitory factor (MIF), TNF-α (36). PD-MSCs extracted from PE patients impede VEGF and β-human Chorionic Gonadotropin (βhCG) expression and stimulate a high level of sFlt-1 secretion to form a PE like phenotype in normal term villous explants (36).

It was newly proved that human CV-MSCs (hCV-MSCs) are abundant with primary cilium (54). They are responsible for cell signaling, differentiation, motility, and homing. Abnormal cillum length was detected in PE-derived hCV-MSCs. It may cripple the differentiation of hCV-MSCs and its interaction with other cells such as trophoblast and endothelial cells in the placenta (HUVeCs), followed by the impaired capacity of hCV-MSCs to foster the growth of human placental organoids and vascular-like network formation.
of Human Umbilical Vein Endothelial Cells (HUVECs) in vitro (54).

**Mesenchymal stem cells in preeclampsia therapy**

Besides responding to growth signals and participating in programmed tissue development, MSCs also act as damage sensors and are recruited to the injury site in response to stress signals (inflammation, hypoxia, and the like) and then take part in tissue repair (55). MSCs replenish injured tissue by both differentiating into tissue cells directly and secreting trophic cytokines to foster the proliferation of tissue cells indirectly. Moreover, inflammatory signals can also stimulate MSCs to an immunosuppressive phenotype thus curbing inflammation/immune activation in injured tissue (43). MSCs-mediated angiogenesis help injured tissue to rebuild the vascular network and recover blood supply. More interestingly, MSCs express low levels of HLA Class I and II and high levels of HLA-G (56, 57), as a consequence, MSCs show relative low immunogenicity after allotransplantation. Paracrine nutrition, multi-differentiation, damage sensing, anti-inflammatory/immune-modulation, and low immunogenicity traits have made MSCs a useful therapeutic agent in the treatment of several diseases, including chronic kidney disease (CKD), multiple sclerosis (MS), and myocardial infarction (MI) (55). MSCs can also be harnessed to combat preeclampsia (PE), a pregnancy-related condition characterized by the uncontrolled proliferation of trophoblasts and vascular leakage in the placenta, which can lead to serious complications and maternal and fetal health risks (54).

| MSCs kinds | miRNA levels in PE | miRNA biotargets | Molecules involved | miRNA bioeffects on MSCs | References |
|------------|-------------------|------------------|-------------------|--------------------------|-----------|
| dMSCs      | miR-136†         | \               | VEGF†             | dMSCs: cell proliferation↑, apoptosis↓, angiogenesis↓ | (147)     |
| hUC-MSCs   | miR-495†         | Bim-1†          | \                | hUC-MSCs: inhibit cell proliferation↓, senescence↑, apoptosis↑, migration↓, invasion↓ | (78)      |
| hUC-MSCs   | miR-181†         | \               | CD450, IL-6†, VEGF†, IDO†, CD8* IFN-γ positive T-cells† | hUC-MSCs: proliferation↓, migration↑, invasion↑ | (148)     |
| hUC-MSCs-Exo | miR-30a†       | TAB3             | \                | hUC-MSCs: cell cycle entry rate↓ | (112)     |
| Bm-MSCs    | IncRNA H19†     | let-7b†          | \                | hUC-MSCs on trophoblasts: migration↑, invasion↑, apoptosis↑ | (149)     |
| hUC-MSCs   | IncRNA MALAT1†  | \               | VEGF†, IDO†      | hUC-MSCs: proliferation↑, apoptosis↑, migration↑, invasion↑ | (114)     |
| hUC-MSC-Exo | MiR-101†        | BRD4             | \                | hUC-MSC: Trophoblasts: migration↑, proliferation↑ | (149)     |
| hUC-MSC-Exo | miRNA-139-5p†  | PTEN                     | \                | hUC-MSCs on trophoblasts: migration↑, invasion↑, apoptosis↑ | (118)     |
| hUC-MSC-Exo | miRN-18b†       | Notch2†          | \                | hUC-MSCs on trophoblasts: proliferation↑, migration↑ | (150)     |

**TABLE 1 miRNA and LncRNA involved in MSCs dysfunction in PE.**

*Notch2, Notch3, Notch4, Notch5; PTEN, Phosphatase and tensin homolog.*
transplantation a potent therapy in tissue repair and systematic inflammation/immune disorders (58). Japan and Europe have approved MSCs products for the clinical treatment of Crohn's fistular and graft vs. host diseases (59). Now, MSCs transplantation becomes a new remedy realized in PE-like animal models.

Mesenchymal stem cells and trophoblasts

Superficial trophoblast invasion in preeclampsia

During placentation, trophoblasts invade the decidua and form the villous, the base functional unit of the placenta. Extravillous trophoblast (EVT) migrates out from the villi to fix to the decidua. Other endovascular EVT invade the spiral arteries to replace the vascular wall (60) and enhance the placental blood supply to the fetus (61, 62). Superficial trophoblast invasion and insufficient placental vascular remodeling were detected in PE patients (33, 63, 64) leading to placental hypoxia/ischemia in PE (65, 66).

Mesenchymal stem cells and trophoblast function

Mesenchymal stem cells derived Exo promote migration, invasion, and proliferation of trophoblasts cell lines in vitro, promoting cell cycle entry and inhibiting apoptosis of these cell lines (67, 68). Both hUC-MSCs and its supernatant can upregulate PGF and β-hCG levels in the HTR8-S/Vneo culture medium and promote the proliferation, migration, and invasion of HTR8-S/Vneo trophoblasts cell line (69). It was reported that the invasiveness of trophoblast is partially regulated by paracrine signaling from PD−MSCs (70). The HGF generated from PD−MSCs promotes trophoblast invasion by upregulating CAMP and Rap1 (71) (Figure 3).

Hypoxia-inducible factor 1-alpha (HIF1-α) is a multifunctional transcription factor involved in regulating energy metabolism, cell survival, invasion, and angiogenesis. HIF1-α is a regulator of ROS to stimulate cell invasion and migration by activating (72) the ERK (73), and Rho (74) family signaling pathways. MMP-2/-9 facilities the invasion process of trophoblast by breaking down the extracellular matrix. It has been found that PD−MSCs promote trophoblasts invasion partially by upregulating HIF1α mRNA and MMP-2/-9 mRNA (74) (Figure 3).

In addition, miRNAs and LncRNAs in MSCs derived Exo MSCs are transferred to the trophoblast to regulate its activities. LncRNA-H19, LncRNA-MALAT, miR-101, miR-133b, and miR-18b in MSCs-Exo promote trophoblast proliferation, migration, and invasion in vitro (Table 1). But these miRNAs and LncRNAs are abnormally expressed in PD-MSCs derived from PE patients (Table 1). For example, LncRNA-H19 in MSCs-Evo targets let-7b to up-regulate FOXO1 to activate the AKT signaling pathway thus increasing invasion/migration and inhibiting apoptosis of trophoblast cells (75) (Figure 3). Another LncRNA named metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is first discovered to prophesy lung cancer metastasis (76, 77) now found to be involved in promoting trophoblast proliferation and invasion. However, low levels of H19 and MALAT1 were detected in hUC-MSCs from PE patients (78). miR-16 and miR-494 inhibit the migration of trophoblast, while they are both up-regulated in PE-derived MSCs (79, 80). After treatment with PE-derived PD−MSCs conditioned media (CM), disturbed JunB/Cyclin D1 balance combined with arrested cell cycle and elevated production of pro-inflammatory cytokines were detected in normal term placental villous explants in vitro (39).

Mesenchymal stem cells regulate autophagy in the trophoblast

Autophagy is important to maintain homeostasis in humans. Lysosomes remove degradation molecules, invading pathogens, and malfunction organelles through autophagy (81). Under hypoxia, ischemia, starvation, or other stress conditions, cells get nutrients and energy partially through activating autophagy (82, 83). Molecules involved in the autophagy process also participate in cell proliferation, differentiation, and senescence signaling pathways (84). Autophagy is crucial for placenta (85). In Syncytiotrophoblasts, autophagy protects the cell from infection, apoptosis, and inflammation (86, 87). In hypoxic/ischemic conditions, placental trophoblasts in PE patients are more reliant on autophagy to survive than cells in the normal placenta (88).

Modulating autophagy is one of the mechanisms involved in the therapeutic effects of MSCs in injury tissue repair (89). MSCs can modulate autophagy in immune cells and facilitate the resolution of injury-related inflammation (89). In addition, MSCs-mediated autophagy promotes the survival, proliferation, and differentiation of tissue stem/progenitor cells to support the restoration of the functional tissue after injury (89). BM-MSC activates the autophagic machinery and promotes the survival of pulmonary cells in ischemia-reperfusion-injury models in vivo and in vitro (90). This effect was also detected in trophoblast (91, 92).

JAK2/STAT3 (92) is the putative upstream regulator activating autophagy while mTOR/Zeste 2 polycomb repressive complex 2 ( EZH2) subunit axes are putative to down-regulate autophagy in cells (93–95). Under the hypoxic condition, AD-MSCs-Exo and CV-MSC conditioned medium boost autophagy, invasion, and survival of trophoblasts by inhibiting the EZH2/mTOR and activating the JAK2/STAT3 signaling pathway in the trophoblast respectively (91, 92) (Figure 3). Blocking the JAK2/STAT3 signaling pathway

Figure 3
FIGURE 3

PD-MSCs support trophoblast invasion and improve survival of trophoblast in hypoxia. PD-MSCs secret multiple cytokines, miRNA, LncRNA, or other undefined signals to facilitate the invasion of trophoblast. PD-MSCs primed autophagy and mitophagy may help trophoblast survive under hypoxic conditions. PD-MSCs promote mitochondrial ATP synthesis through glycolysis and oxidative phosphorylation which increase the energy supply for trophoblast activities and survival under hypoxic conditions. (I) After preconditioned in a hypoxic environment, PD-MSCs co-cultivation improves PINK1 accumulation in MT, and then PINK1 interacts with PARKIN to induce mitophagy in trophoblast. (II) PD-MSCs promote Ca$^{2+}$ commuting between ER and MT through activating IP3R/MCU in the trophoblast. (III) PD-MSCs upregulate HIF-1$\alpha$ in trophoblast followed by a moderate surge of ROS flux to activate the invasion ability of trophoblast, however, PD-MSCs also promote the expression of HMOX1/2 in trophoblast to curb excessive oxidative injury induced by ROS. ER, Endoplasmic reticulum; MT, Mitochondrial; EZH2, Zeste 2 polycomb repressive complex 2; IP3R, Inositol 1,4,5-trisphosphate; MCU, Mitochondrial calcium uniporter; VDAC, Voltage-dependent anion-selective channel; PINK1, Phosphatase and tensin homolog (PTEN)-induced kinase 1; PARKIN, Parkin RBR E3 ubiquitin-protein ligase.

Placenta derived MSCs and trophoblast interaction

PD-MSCs support trophoblast invasion and improve survival of trophoblast in hypoxia. PD-MSCs secret multiple cytokines, miRNA, LncRNA, or other undefined signals to facilitate the invasion of trophoblast. PD-MSCs primed autophagy and mitophagy may help trophoblast survive under hypoxic conditions. PD-MSCs promote mitochondrial ATP synthesis through glycolysis and oxidative phosphorylation which increase the energy supply for trophoblast activities and survival under hypoxic conditions. (I) After preconditioned in a hypoxic environment, PD-MSCs co-cultivation improves PINK1 accumulation in MT, and then PINK1 interacts with PARKIN to induce mitophagy in trophoblast. (II) PD-MSCs promote Ca$^{2+}$ commuting between ER and MT through activating IP3R/MCU in the trophoblast. (III) PD-MSCs upregulate HIF-1$\alpha$ in trophoblast followed by a moderate surge of ROS flux to activate the invasion ability of trophoblast, however, PD-MSCs also promote the expression of HMOX1/2 in trophoblast to curb excessive oxidative injury induced by ROS. ER, Endoplasmic reticulum; MT, Mitochondrial; EZH2, Zeste 2 polycomb repressive complex 2; IP3R, Inositol 1,4,5-trisphosphate; MCU, Mitochondrial calcium uniporter; VDAC, Voltage-dependent anion-selective channel; PINK1, Phosphatase and tensin homolog (PTEN)-induced kinase 1; PARKIN, Parkin RBR E3 ubiquitin-protein ligase.

or stimulating the expression of EZH2 or administration of autophagy inhibitor 3-MA can reduce MSCs cultivation mediated autophagy, invasion, and survival of trophoblasts (91, 92).

Mesenchymal stem cells regulate mitochondrial metabolism

High-energy cells like trophoblast rely intensely on mitochondrial ATP synthesis to function normally and then establish a successful pregnancy. PD-MSC cocultivation improves glycolysis and mitochondrial respiration (74). It improves cellular ATP synthesis and consumption via activating the Ca$^{2+}$ movement between the endoplasmic reticulum (ER) and mitochondria in invasive trophoblasts and significantly increases trophoblasts’ invasion ability (74). Inositol 1,4,5-trisphosphate (IP3R) in ER interacts with mitochondrial calcium uniporter (MCU) and voltage-dependent anion-selective channel (VDAC) (an ion channel in the outer membrane of mitochondria) and plays a role in calcium transportation (96–98) (Figure 3). Cellular levels of MCU, VDAC, and IP3R all increased in trophoblast after PD-MSCs co-cultivation (74) (Figure 3).

In PE patients, placenta hypoxia/ischemia-induced oxidative stress results in mitochondria dysfunction and then cell apoptosis. Several studies showed smaller mitochondria and increased ROS levels in trophoblast extracted from the placenta of women with PE, indicating a mitochondrial malfunction in trophoblast cells (99).

Hypoxia brings on disarrangement of mitochondrial ultrastructure in mice trophoblasts in vitro. bm-MSCs intensify mitochondrial membrane potential and increase ATP production/consumption in trophoblast and support cell survival against hypoxia (100). PD−MSCs reduce
mitochondrial damage by downregulating Heat shock protein 60 (HSP60) (induced under mitochondrial stress) and upregulating prohibitin 1 (PHB1) (involved in stabilizing mitochondria) expression and promoting ATP generation/consumption by upregulating VCAC in the mitochondria of trophoblast cells (101).

ROS is generated dynamically in cell metabolism or under stress conditions, and it is degraded by antioxidant enzymes to keep ROS at an appropriate level in mitochondria. ATP production/consumption and oxidative phosphorylation (OXPHOS) synchronously increase with the invasiveness of cells (102). Mitochondrial ROS (mtROS) promotes cell migration via the NADPH oxidase (NOX) signaling pathway (102). Moreover, mtROS signal promotes structure stability of MMP9 mRNA to upregulate cell invasiveness (103). PD-MSCs co-cultivation activates the HIF1-α/ROS/MMPs stream to promote the invasion of trophoblast through the ERK signaling pathway (73). While, excessive ROS accumulation impairs the invasiveness of trophoblasts through downregulating integrin b3 and FOXO1 (104, 105). HMOX1/2 are genes targeting ROS to manage oxidative stress. After cocultured with PD-MSCs, HMOX1/2 mRNA and protein levels were increased in trophoblasts compared to uncultured ones. This data indicate that MSCs play a role in balancing ROS to facilitate trophoblast invasion while avoiding a high level of ROS-mediated cell injury (74, 101) (Figure 3).

Mesenchymal stem cells regulate mitophagy in the trophoblast

Mitochondrial autophagy (mitophagy) is a self-protection mechanism of cells under stress, which is usually triggered by damaged mitochondrial. Persistent hypoxia induces mitophagy to clear the damaged mitochondria and keep cellular homeostasis (106). Phosphatase and tensin homolog (PTEN)-induced kinase 1 (PINK1) and Parkin RBR E3 ubiquitin-protein ligase (PARKIN) are two mitophagy regulators. It was reported that PINK1 modulates mitochondrial metabolism, and calcium homeostasis (107). PINK1 binds with PARKIN to recognize the proteins on the outer membrane of mitochondria and mediate autophagy to remove the damaged mitochondria. PD-MSCs cocultivation up-regulates the expression of PINK1 and PARKIN in the trophoblast and protects trophoblast survival from hypoxia (101, 108) (Figure 3).

In all, MSCs promote the proliferation and function of trophoblast cells via the paracrine pathway, and these effects were attenuated in PE-derived MSCs. By facilitating mitochondrial metabolism, stabilizing the mitochondrial membrane, and modulating the autophagy and mitophagy in the trophoblast, MSCs promote the survival of the trophoblast and maintain its proliferation, migration, and invasion under hypoxic conditions. MSCs supplementation may help restore the trophoblast function in the hypoxic placenta in PE patients.

Mesenchymal stem cells in inflammation/immune modulation

Local and systematic inflammation along with excessive immune activation was detected in PE gestation. The inflammatory process mediates placenta and systematic vascular endothelial injury and angiogenesis disorder in PE. Persistent hypoxia-related oxidative stress induces high amounts of DAMP generated in the placenta, which activate the innate and adaptive immune systems. Neutrophils, monocytes, NK cells, DCs are all possible objective cells involved in inflammation conditions in PE (109).

Mesenchymal stem cells is a stress sensors. Under the inflammatory condition, MSCs cell-to-cell contact with macrophages, monocytes, dendritic cells (DCs), natural killer (NK) cells, T cells, and B cells as well as release paracrine cytokines like prostanooid E2 (PEG2), indoleamine 2,3-dioxygenase (IDO), TGF-β1, HGF, and nitric oxide (NO) to regulate innate and adaptive immunity (43).

Mesenchymal stem cells are involved in regulating the immune response in decidual. dMSCs upregulate KIR2DL1, and IL-4, and downregulate the expressions of NKp30 and TNF-α thus inducing a tolerance phenotype of dNK cells (110). After co-culture with immune cells isolated from decidual tissue, UC-MSCs promote the expansion of decidual Treg cells (dTreg), inhibit effector T cells proliferation, enhance Th2-type cytokines secretion in T cells, and enhance the potency of dTreg to suppress Th1 and Th17 mediated inflammation (111). MSCs secrete TSG-6 or cell-to-cell contact with pro-inflammatory macrophages through CD200/CD200R axis to educate macrophages toward an anti-inflammatory phenotype. The immunomodulatory effects of MSCs are usually activated in inflammatory conditions (43). MSCs may contribute to the transition of the early stage Th1 inflammation state in the maternal-fetal interface to the immune tolerance state in the second trimester of pregnancy (Figure 4).

miRNA/LncRNA expression disorder in patients with PE can disturb the immune-modulatory function of MSCs in the placenta (Table 1). MiR-30a and miR-494 are up-regulated in hUC-MSCs derived from PE patients. IL-1β-pretreated hUC-MSCs significantly reduce lipopolysaccharide (LPS) elicited IL-6 and TNF-a expression in macrophages and facilitate CD4+CD25+Foxp3+ Treg cells expansion, but miR-30a transfection impairs these anti-inflammatory effects of hUC-MSCs through targeting at transforming growth factor-β-activated kinase 1 binding protein 3 (TAB3) (112). miR-494 reduces PGE2 secretion in decidual MSCs (dMSCs) and attenuates PGE2 mediated M2 macrophage (anti-inflammatory phenotype) polarization in vitro (113).
MALAT1 induces IDO expression in UC-MSCs and promotes M2 macrophage polarization in vitro, however, the level of LncRNA-MALAT1 decreased in UC-MSCs in patients with severe PE (114).

Mesenchymal stem cells have immune-modulatory and anti-inflammatory potency thus they have been used in a variety of inflammation-related diseases, such as graft vs. host disease and Crohn’s disease (115). MSCs or MSCs-EVs were also found to have in vivo anti-inflammatory effects in N-nitro-L-arginine methyl ester (L-NAME) (116), LPS (117), endotoxin (118), or Th1 cell-induced PE-like mouse model (119). Intravenous administration of MSCs or MSCs-Exo reduces inflammatory cytokines such as TNF-α, IL-1β, and IL-6 in PE mice on the contrary increasing IL-10 and PPARγ levels in it (Table 2). In addition, experiments also confirmed that MSCs had a direct effect on LPS-induced trophoblast inflammation in vitro. After LPS pretreated trophoblast cocultured with AF-MSC, miR-146a-5p was upregulated in trophoblast cells. miR-146a-5p in AF-MSCs derived Exo suppress the inflammatory pathway like NFκB and MAPKs in trophoblast after treatment with LPS (120). This may be one of the mechanisms by which MSCs promote the survival of trophoblasts in PE-related placental inflammatory environments.

Mesenchymal stem cells and oxidative stress in preeclampsia

As mentioned earlier, MSCs participate in the antioxidant stress process by promoting trophoblast autophagy, regulating mitochondrial metabolism, promoting mitochondrial autophagy, and balancing ROS levels, to induce trophoblast survival in hypoxic conditions. Aldehyde dehydrogenases (ALDH) are enzymes detoxifying aldehydes generated under oxidative stress. Immunohistochemical localization found that ALDH was co-localized with the FZD-9 (a specific MSCs marker) in maternal decidua basalis. MSCs derived from the placenta show high ALDH activity under oxidative stress (121). ALDH1A1 mRNA level and ALDH enzyme activity are decreased in PE dMSCs relative to normal dMSCs. PE-derived dMSCs have an impaired response to oxidative stress with increased ROS levels in them (122). Moreover, PD-MSCs secreted paracrine factors trigger STAT3 activation and superoxide dismutase 2 (SOD2) production to support endothelial cell survival under tert-Butyl hydroperoxide induced oxidative injury (123). dMSCs significantly enhance the activities of glutathione and thioredoxin reductases in H₂O₂ preconditioned HUVECs and restore their function (124). In addition, dMSC-EVs significantly reduce the level of lipid peroxidation in PE serum treated HUVECs (125).

Mesenchymal stem cells in angiogenesis

Mesenchymal stem cells are involved in both vasculogenesis and angiogenesis processes in vitro. Pluripotent mesenchymal cells differentiate into multiple cell lineages like endothelial cells and smooth muscle cells to constitutively form vascular de novo (defined as vasculogenesis) (126) (Figure 1). PD-MSCs...
dysfunction and angiogenic disorder in patients with PE process (130). sFlt-1/VEGF imbalance leads to endothelial binds to VEGF and PGF to inhibit their proangiogenic elevated in the placenta and serum of PE patients. sFlt-1 was compromised. the angiogenesis potency of PD-MSCs from PE patients gestational tissue-derived MSCs have strong therapeutic to bm-MSCs and UC-MSCs (128). Endometrial and exhibited superior pro-angiogenesis potential compared

Figure 1 (127) (defined as angiogenesis) (131, 132). The sFlt-1/VEGF ratio has emerged as a key biochemical indicator for predicting the risk of PE (113). Treating villous explants from normal placenta with PE-derived PD-MSCs conditioned media, the villous showed significantly increased expression of sFlt-1 and decreased derived PD-MSCs conditioned media, the villous showed

TABLE 2 MSCs and its derivants transplantation in PE-like animal models.

| MSCs kinds | Animals | PE-like modeling | Route of MSCs administration | Bioeffects of MSCs administration | References |
|------------|---------|------------------|-------------------------------|----------------------------------|------------|
| hUC-MSCs   | Rat     | LPS (i.v.)       | 2 x 10^6 cells per mouse (i.v.) once | BP↓, TNF-α↓, IL-6↓, IL-12↓, ICAM-1↓, IL-10↑ | (100)      |
| hdMSCs     | Mice    | activated Th1 cells (i.v.) | 100 μl (10^6 cells/100 ml, i.v.) on day 11.5 and day 13.5 of gestation | BP↓, UP↑, fetal weight↑, fetal loss rate↓, TNF-α↓, placental and glomerular injury↓ | (73)       |
| hUC-MSCs   | Rat     | endotoxin solution (i.v.) | 100 μl (2 x 10^6 cells/100 μl, i.v.) once | BP↓, UP↑, TNF-α↓, IL-1β↓, IL-10↑ | (151)      |
| HMOX1 modified hPD-MSCs | Rat | L-NAME (i.p.) | 25 μl (5 x 10^7) injected into placenta | BP↑, UP↑, placental and fetal weight↑, placental perfusion↑, placental angiogenesis balance↑ (MVD↑, VEGF↑, and PlGF↑, sFlt-1↓, and sFlt-1↓) | (137)      |
| hUC-MSC-Exo | Rat | L-NAME (i.p.) | 0.5 ml/rat/day (120 μg/ml, i.p.), totally 6 days | BP↑, UP↑ | (94)       |
| hUC-MSCs-EVs | Rat | L-NAME (s.c.) | Not detailedly mentioned | BP↑, UP↑, apoptotic cell rate in placenta↓ | (150)      |
| hUC-MSC-Exo | Rat | L-NAME (i.p.) | 0.5 ml/rat/day (i.v., low (120 μg/ml), middle (140 μg/ml), high (160 μg/ml) level), totally 6 days | BP↑, UP↑, fetal numbers↑, placental and fetal weight↑, apoptotic cell rate in placenta↑, placental angiogenesis balance↑ (MVD↑, VEGF↑, sFlt1↑) | (138)      |
| hUC-MSC-EVs | Mice | HMOX1 null mice model | 5 x 10^6 cells equivalents (i.v.) once | BP↑, UP↑, fetal loss rate↑, fetal length↑, placental and kidney injury↑, placental spiral artery humen wall ratio↑, placental sNOS and myeloid cell numbers↑, CD44, CD103, and CD64 level in myeloid populations↑, IL-10 and IFN-γ↑ | (152)      |
| hPD-MSCs-CM | Mice | LPS (i.v.) | 300 μL (i.v.) once | BP↑, UP↑, placental weight↑, sFlt-1↓, IL-6↓, and TNF-α↓ | (153)      |
| hUC-MSCs-Exo | Rat | L-NAME (i.p.) | 20 μl/rat/day (80 μg/20 μL, i.p.) on day 16 to day 19 of gestation | BP↑, UP↑, fetal and placenta weights↑, TNF-α↓, IL-1β↓, IL-6↓, apoptotic cell rate in placenta↓ | (116)      |
| MiR-101 modified hUC-MSC-EVs | Rat | L-NAME (i.p.) | 140 μg/ ml since the 14th day of pregnancy for 6 days (i.p.) | BP↑, 24-h UP↑, fetus and placental weight↑, placenta injury↑, CXCL11↑, IL-6↓, TNF-α↓, p-IkBα↑, p-IEKβ↑ | (149)      |

L-NAME, NG-nitro-L-arginine methyl ester; i.p., intraperitoneal injection; i.v, intravenously injection; BP, blood pressure; UP, urine protein.

secrete various angiogenic agents like VEGF, and HGF which promote preexisting endothelial progenitor cell migration, promotion, tube formation, and sprouting to form a stable vessel network and regulate angiogenesis under the stimulation signals like hypoxia and growth (127) (defined as angiogenesis) (Figure 1). PD-MSCs exhibited superior pro-angiogenesis potential compared to bm-MSCs and UC-MSCs (128). Endometrial and gestational tissue-derived MSCs have strong therapeutic angiogenesis in clinical and experimental use (129). However, the angiogenesis potency of PD-MSCs from PE patients was compromised.

Angiogenic imbalance is one of the key steps in the pathogenesis of PE. Antiangiogenic protein sFlt-1 is elevated in the placenta and serum of PE patients. sFlt-1 binds to VEGF and PGF to inhibit their proangiogenic process (130). sFlt-1/VEGF imbalance leads to endothelial dysfunction and angiogenic disorder in patients with PE (131, 132). The sFlt-1/VEGF ratio has emerged as a key biochemical indicator for predicting the risk of PE (113). Treating villous explants from normal placenta with PE-derived PD-MSCs conditioned media, the villous showed significantly increased expression of sFlt-1 and decreased VEGF protein level compared to the normal PD-MSCs group (36).

PD-MSCs and their derived EVs promote HUVECs tube formation in vitro. HMOX1 is a stress-response protein with pro-angiogenic properties (133–135). HMOX1 modified PD-MSCs show higher efficiency than the unmodified ones in promoting HUVECs tube formation (136). In the L-NAME-induced PE-like rat model, HMOX1 modified PD-MSCs restore VEGF/sFlt-1 balance to form a proangiogenic state in vivo and increase microvascular density (MVD) in the placenta (137). Intravenous administration of hUC-MSCs-Exo could significantly alleviate endothelial nitric oxide synthase induced placental angiogenesis disorder,
in vivo, inflammatory and immunomodulatory potencies of MSCs contribute to embryo implantation (7, 139, 140). MSCs are actively recruited to decidual and trophoderm secretomes chemotaxis peripheral blood in vivo of it homing to the injury site. These may explain the limited administered MSCs going through lung arrest and only a little rejection result in a short half-life of MSCs cultivation and administration. MSCs apoptosis and immune differentiation, loss of stemness, and senescence of MSCs during therapy. Scientists are trying to solve the problems of automatic in PE mice therapy. Table 2 included in explain these traits in perinatal tissue-derived MSCs. All studies immune microenvironment of MSCs in the placenta may rejection in clinical application (56). The unique growth and derived MSCs express lower levels of HLA class I and II and and preclinical studies (56). Meanwhile, placental neonate-derived MSCs express lower levels of HLA class I and II and higher proliferation efficiency (56), superior regenerative and immunosuppressive activities in some clinical and preclinical studies (56). Meanwhile, placental neonate-derived MSCs express lower levels of HLA class I and II and higher levels of HLA-G, which may reduce the risk of immune rejection in clinical application (56). The unique growth and immune microenvironment of MSCs in the placenta may explain these traits in perinatal tissue-derived MSCs. All studies in Table 2 have chosen perinatal tissue-derived MSCs in PE mice therapy.

Efficacy and safety are two major concerns in MSCs therapy. Scientists are trying to solve the problems of automatic differentiation, loss of stemness, and senescence of MSCs during cultivation and administration. MSCs apoptosis and immune rejection result in a short half-life of MSCs in vivo. Intravenously administered MSCs going through lung arrest and only a little of it homing to the injury site. These may explain the limited therapeutic potency of MSCs in vivo.

Implantation cytokine (IFN-τ) and embryonic trophoderm secretomes chemotaxis peripheral blood MSCs and adult bone marrow progenitors toward the uterus (7, 139, 140). MSCs are actively recruited to decidual and contribute to embryo implantation (7, 139, 140) and may also play role in controlling embryo implantation provoked inflammation because inflammatory signals activate the anti-inflammatory and immunomodulatory potencies of MSCs (141). In vivo, optical data shows that intravenous transferred Zs-Green + MSCs were predominantly distributed in the pregnant uterus than in the virgin uterus in mice and increased in LPS-induced inflammatory pregnant uterus in a further step. The advantageous biological distribution of MSCs in pregnant tissues may encourage MSCs in treating pregnancy diseases (141). Though MSCs have low immunogenicity, allogeneic MSCs transplants may also induce immune rejection. Transplanted MSCs die rapidly then it be cleared by innate immune cells (142, 143). Whether the immune-privileged maternal-fetal interface will benefit the survival of allogeneic MSCs is an interesting perspective to investigate.

Mesenchymal stem cells have shown high safety in clinical and experimental studies, but there are still several important issues that need to be treated carefully because safety is the most basic prerequisite for the application of any kind of treatment. Although MSCs do not have a direct tumorigenic effect, MSCs have the risk of promoting tumor growth in tumor patients (144). Trophoblast cells have biological characteristics similar to those of tumor cells. Large-scale experimental observation is needed to determine whether MSCs will increase the risk of abnormal invasion of trophoblast or even choriocarcinoma. MSCs treatment is associated with an increased risk of thrombosis (145). It is open to debate whether MSCs adoption further raises the risk of thrombosis under preexisting physiologic hypercoagulation state during pregnancy, especially in the third trimester of pregnancy.

Exo is naturally generated nanosized vesicles containing growth factors, cytokines, lipids, regulatory miRNAs, and DNA. These vesicles comprise natural lipid bilayers embed with an abundance of adhesive proteins and readily interact and fuse with cellular membranes (146). Exo is involved in cell-to-cell signaling communication at short or long distances and can respond to tissue injury, infection, and disease. MSCs-Exo is with many traits of MSCs in the treatment of hypoxia-induced tissue injury (146). MSCs-Exo also has therapeutic effects on PE as to current mice data, and it shows lower immunogenicity and higher therapeutic safety, thus MSCs-Exo will be a good substitute for MSCs. Meanwhile, we may further improve the therapeutic effect of MSCs and MSCs-Exo through gene modification strategies.

Limitations and prospects

Among the 11 PE animal pieces of research (Table 2), including 4 MSCs-based studies and 7 MSCs derivates (6 MSCs-Exo and 1 MSCs-CM) based studies. MiR-101 transfection and HMOX1 gene-modifying enhance the efficacy of hUC-MSC-EVs and hPD-MSCs in PE mice therapy, respectively. MiR-18b-3p, MiRNA-101, and MiR-139-5p are molecules in MSCs-Exo partially responsible for relieving symptoms and improving pregnancy outcomes in PE mice. One study found dose-dependent therapeutic effects of MSC-Exo on PE mice. How PE modeling, MSCs cell types, and administration routes influence therapeutic efficacy in PE mice can’t be concluded from these data, and also, no systematic experimental design was conducted to evaluate the toxicity of MSCs administration during pregnancy.

Bone marrow, adipose, and perinatal tissues are important sources of MSCs. The special phenotype of MSCs from different tissues affects their safety and efficiency in treatment. In recent years, more and more attention has been paid to the clinical application of perinatal tissue-derived MSCs. Many shreds of evidence support that MSCs from gestational tissue show lower aging rates and higher proliferation efficiency (56), superior regenerative and immunosuppressive enhancement in some clinical and preclinical studies (56). Meanwhile, placental neonate-derived MSCs express lower levels of HLA class I and II and higher levels of HLA-G, which may reduce the risk of immune rejection in clinical application (56). The unique growth and immune microenvironment of MSCs in the placenta may explain these traits in perinatal tissue-derived MSCs. All studies included in Table 2 have chosen perinatal tissue-derived MSCs in PE mice therapy.

Efficacy and safety are two major concerns in MSCs therapy. Scientists are trying to solve the problems of automatic differentiation, loss of stemness, and senescence of MSCs during cultivation and administration. MSCs apoptosis and immune rejection result in a short half-life of MSCs in vivo. Intravenously administered MSCs going through lung arrest and only a little of it homing to the injury site. These may explain the limited therapeutic potency of MSCs in vivo.

Implantation cytokine (IFN-τ) and embryonic trophoderm secretomes chemotaxis peripheral blood MSCs and adult bone marrow progenitors toward the uterus (7, 139, 140). MSCs are actively recruited to decidual and contribute to embryo implantation (7, 139, 140) and may also play role in controlling embryo implantation provoked inflammation because inflammatory signals activate the anti-inflammatory and immunomodulatory potencies of MSCs (141). In vivo, optical data shows that intravenous transferred Zs-Green + MSCs were predominantly distributed in the pregnant uterus than in the virgin uterus in mice and increased in LPS-induced inflammatory pregnant uterus in a further step. The advantageous biological distribution of MSCs in pregnant tissues may encourage MSCs in treating pregnancy diseases (141). Though MSCs have low immunogenicity, allogeneic MSCs transplants may also induce immune rejection. Transplanted MSCs die rapidly then it be cleared by innate immune cells (142, 143). Whether the immune-privileged maternal-fetal interface will benefit the survival of allogeneic MSCs is an interesting perspective to investigate.

Mesenchymal stem cells have shown high safety in clinical and experimental studies, but there are still several important issues that need to be treated carefully because safety is the most basic prerequisite for the application of any kind of treatment. Although MSCs do not have a direct tumorigenic effect, MSCs have the risk of promoting tumor growth in tumor patients (144). Trophoblast cells have biological characteristics similar to those of tumor cells. Large-scale experimental observation is needed to determine whether MSCs will increase the risk of abnormal invasion of trophoblast or even choriocarcinoma. MSCs treatment is associated with an increased risk of thrombosis (145). It is open to debate whether MSCs adoption further raises the risk of thrombosis under preexisting physiologic hypercoagulation state during pregnancy, especially in the third trimester of pregnancy.

Exo is naturally generated nanosized vesicles containing growth factors, cytokines, lipids, regulatory miRNAs, and DNA. These vesicles comprise natural lipid bilayers embed with an abundance of adhesive proteins and readily interact and fuse with cellular membranes (146). Exo is involved in cell-to-cell signaling communication at short or long distances and can respond to tissue injury, infection, and disease. MSCs-Exo is with many traits of MSCs in the treatment of hypoxia-induced tissue injury (146). MSCs-Exo also has therapeutic effects on PE as to current mice data, and it shows lower immunogenicity and higher therapeutic safety, thus MSCs-Exo will be a good substitute for MSCs. Meanwhile, we may further improve the therapeutic effect of MSCs and MSCs-Exo through gene modification strategies.

Author contributions

SJ was responsible for the data collation and full-text writing of this article. MC, CW, DS, and HZ were responsible for the proofreading of this article. HZ also funded this article. All authors contributed to the article and approved the submitted version.

Funding

This article was funded by the Sixth Batch of National Senior TCM Experts Academic Experience Inheritance Project...
Conflict of interest

The authors declare that there is no conflict of interest in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Gargett CE, Schwab KE, Deane JA. Endometrial stem/progenitor cells: the first 10 years. Hum Reprod Update. (2016) 22:137–63. doi: 10.1093/humupd/dmv051
2. Masuda H, Anwar SS, Bühring H-J, Rao JR, Gargett CE. A novel marker of human endometrial mesenchymal stem-like cells. Cell Transplant. (2012) 21:2201–14. doi: 10.3727/096689111X6437662
3. Rungsiwut R, Viratamasen P, Pruksananonda K. Mesenchymal stem cells for restoring endometrial function: an infertility perspective. Reprod Med Biol. (2021) 20:13–9. doi: 10.1002/rmb2.12339
4. Zhu X, Paulyt J, Yan G, Ding L. Stem cells and endometrial regeneration: from basic research to clinical trial. Curr Stem Cell Res Ther. (2019) 14:293–304. doi: 10.2174/15748881466681205120110
5. Cha J, Sun X, Dey SK. Mechanisms of implantation: strategies for successful pregnancy. Nat Med. (2012) 18:1754–67. doi: 10.1038/nm.3102
6. Ochoa-Bernal MA, Fazleabas AT. Physiologic events of embryo implantation and decidualization in human and non-human primates. Int J Mol Sci. (2020) 21:1973. doi: 10.3390/ijms21061973
7. Tal R, Shaiik S, Pallavi P, Tal A, López-Giráldez F, Lye F, et al. Adult bone marrow progenitors become decidual cells and contribute to embryo implantation and pregnancy. PLoS Biol. (2019) 17:e3000421. doi: 10.1371/journal.pbio.3000421
8. Ticconi C, Pietropolli A, Di Simone N, Piccione E, Fazleabas A. Endometrial immune dysfunction in recurrent pregnancy loss. Int J Mol Sci. (2019) 20:5332. doi: 10.3390/ijms20215332
9. Conrad KP, Rabaglio MB, Post Uiterweer ED. Emerging role for dysregulated decidualization in the genesis of preeclampsia. Placenta. (2017) 60:119–29. doi: 10.1016/j.placenta.2017.06.005
10. Caplan AL, Correa D. The MSC: an injury drugstore. Cell Stem Cell. (2011) 9:11–5. doi: 10.1016/j.stem.2011.06.008
11. da Silva Melreilles L, Malta TM, Panepucci RA, da Silva WJ. Transcriptomic comparisons between cultured human adipose tissue-derived pericytes and mesenchymal stem cells. Genom Data. (2016) 7:20–5. doi: 10.1016/j.gdata.2015.11.009
12. Gellersen B, Brossen J. Cyclic AMP and progesterone receptor cross-talk in human endometrium: a decidualizing affair. J Endocrinol. (2003) 178:357–72. doi: 10.1677/joe.0.1780357
13. Ruiz-Magaña MJ, Martinez-Aguilar R, Llorca T, Abadia-Molina AC, Ruiz-C, Olivares EG. Decidualization modulates the mesenchymal stromal/stem cell and pericyte characteristics of human decidual stromal cells. Effects on antigen presentation, chemotactic activity on monocytes and antitumoral activity. J Reprod Immunol. (2016) 115:103326. doi: 10.1016/j.jri.2016.103326
14. Esmailizadeh S, Mohammadi A, Mahdinejad N, Ghofrani F, Ghasemzadeh-Hassankolaei M. Receptivity markers in endometrial mesenchymal stem cells of recurrent implantation failure and non-recurrent implantation failure women: a pilot study. J Obstet Gynaecol Res. (2020) 46:1393–402. doi: 10.1111/jog.14340
15. Boss AL, Chanley LW, James JL. Placental formation in early pregnancy: how is the centre of the placenta made? Hum Reprod Update. (2018) 24:750–60. doi: 10.1093/humupd/dmy030
16. Jones GN, Moschidou D, Puga-Iglesias T-I, Kuleszewicz K, Vanelme E, Shelbione SJ, et al. Ontological differences in first compared to third trimester human female placental chorionic stem cells. PLoS One. (2012) 7:e43395. doi: 10.1371/journal.pone.0043395
17. Mathew SA, Naik C, Cahill PA, Bhonde RR. Placental mesenchymal stromal cells as an alternative tool for therapeutic angiogenesis. Cell Med Life Sci. (2020) 77:253–65. doi: 10.1007/s00018-019-03268-1
18. Dafary GS, Taylor HS. Implantation in the human: the role of HOX genes. Semin Reprod Med. (2000) 18:311–20. doi: 10.1055/s-2000-12568
19. Rux DR, Song JY, Swinehart JT, Pineault KM, Schlientz AJ, Trulik KG, et al. Regionally restricted hox function in adult bone marrow multipotent mesenchymal stromal/stem cells. Dev Cell. (2016) 39:653–66. doi: 10.1016/j.develcel.2016.11.008
20. Diniz-da-Costa M, Kong CS, Fishwick KJ, Rawlings T, Brightman PJ, Hawkes A, et al. Characterization of highly proliferative decidual precursor cells during the window of implantation in human endometrium. Stem Cells. (2021) 39:1067–80. doi: 10.1002/stem.3367
21. Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. (2013) 170:1–7. doi: 10.1016/j.ejogrb.2013.05.005
22. Dudley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. (2009) 33:160–7. doi: 10.1053/j.semperi.2009.02.010
23. Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol. (2014) 10:466–80. doi: 10.1038/nrneph.2014.102
24. Banerjee S, Huang Z, Wang Z, Nakashima A, Saito S, Sharma S, et al. Etiological value of sterile inflammation in preeclampsia: is it a non-infectious pregnancy complication? Front Cell Dev Biol. (2021) 9:649298. doi: 10.3389/fcell.2021.649298
25. Roberts JM, Hubel CA. Is oxidative stress the link in the two-stage model of pre-eclampsia? Lancet. (1999) 354:788–9. doi: 10.1016/S0140-6736(99)80500-2.
26. Burton GJ, Yung H-W. Endoplasmic reticulum stress in the pathogenesis of early-onset pre-eclampsia. Pregnancy Hypertens. (2011) 1:72–8. doi: 10.1016/j.preghy.2010.12.002
27. Nakashima A, Cheng S-B, Ikawa M, Yoshimori T, Huber WJ, Menon R, et al. Evidence for lysosomal biogenesis proteome defect and impaired autophagy in preeclampsia. PLoS Pathog. (2020) 16:1771–85. doi: 10.1093/oxfordhb/978019085
28. Huppertz B, Kingdom J, Caniggia I, Desoe G, Black S, Korr H, et al. Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation. Placenta. (2003) 24:181–90. doi: 10.1016/S0143-4020(02)00903-X
29. Margioulou-Sarkou G, Margioulou-Sarkou C, Petoussia S, Margaritis K, Varoudiudis E, Gullo G, et al. The role of endoglin and its soluble form in pathogenesis of preeclampsia. Mol Cell Biochem. (2022) 477:479–91. doi: 10.1007/s11010-021-04294-z
30. Soleymanlou N, Jurisica I, Nevo O, Jettea F, Zhang X, Zamudio S, et al. Molecular evidence of placental hypoxygenisation in preeclampsia. J Clin Endocrinol Metab. (2005) 90:4299–308. doi: 10.1210/jc.2005-0078
31. Cheng S-B, Davis S, Sharma S. Maternal-fetal cross talk through cell-free fetal DNA, telomere shortening, microchimerism, and
inflammation. *Am J Reprod Immunol.* (2018) 79:e12851. doi: 10.1111/aji.12851

32. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. *Am J Obstet Gynecol.* (1999) 180:499–506. doi: 10.1016/s0002-9378(97)02399-5

33. Ives CW, Sinkey R, Rajapreyar I, Tita ATN, Oparil S. Preeclampsia-pathophysiology and clinical presentations JACC State-of-the-art review. *J Am Coll Cardiol.* (2020) 76:1560–72. doi: 10.1016/j.jacc.2020.08.014

34. Hwang HS, Maeng YS. Comparative analysis of human umbilical cord blood-derived mesenchymal stem cells between preeclampsia and normal pregnant women. *Stem Cells Int.* (2020) 2020:8430192. doi: 10.1155/2020/8430192

35. Nuzzo AM, Giuffrida D, Zenerito C, Piazzese A, Olearo E, Todoros T, et al. JunB/Cyclin-D1 imbalance in placental mesenchymal stromal cells derived from preeclampsia can be reversed by adalimumab. *PLoS One.* (2014) 9:e86540. doi: 10.1371/journal.pone.0086540

36. Rolfo A, Giuffrida D, Nuzzo AM, Pierobon D, Cardaropoli S, Piccoli E, et al. Pro-inflammatory profile of preeclamptic placental mesenchymal stromal cells narrows down the etiopathogenesis of preeclampsia. *PLoS One.* (2013) 8:e64903. doi: 10.1371/journal.pone.0064903

37. Basmaci YS, Algirdis A, Alenzio R, Al Subayil A, Alaya A, Khalatini T. HMOX1 is partly responsible for phenotypic and functional abnormalities in mesenchymal stem cells/stromal cells from placentas of PE patients. *Stem Cell Res Ther.* (2020) 11:1–14. doi: 10.1186/s13287-020-1557-6

38. Dulak J, Deshe J, Jozkowicz A, Agarwal A. Heme oxygenase-1 and carbon monoxide in vascular pathology: focus on angiogenesis. *Circulation.* (2008) 117:231–41. doi: 10.1161/CIRCULATIONAHA.107.698316

39. Nuzzo AM, Giuffrida D, Masturzo B, Mele P, Piccoli E, Eva C, et al. Altered expression of Gfi1/S phase cell cycle regulators in placental mesenchymal stromal cells derived from preeclamptic pregnancies with fetal placental compromise. *Cell Cycle.* (2017) 16:200–12. doi: 10.1080/15384101.2016.1216766

40. Chang H-H, Hsu S-P, Chien C-T. Interalveolar transplacement of hypoxic preconditioned mesenchymal stem cells improves glomerulonephritis through anti-oxidation, anti-ER Stress, anti-inflammation, anti-apoptosis, and anti-antiphosphorylation. *Antioxidants.* (2019) 9:2. doi: 10.3390/antiox9020002

41. Wobma HM, Tamargo MA, Goeta S, Brown LM, Duran-Struuck R, Vunjak-Novakovic G. The influence of hypoxia and IFN-γ on the proteome and metabolism of therapeutic mesenchymal stem cells. *Biomaterials.* (2018) 167:223–44. doi: 10.1016/j.biomaterials.2018.03.027

42. Tian X-Q, Yang Y-L, Li Q, Huang P-S, Li X-D, Jin C, et al. Globular adpoxenone inhibits the apoptosis of mesenchymal stem cells induced by hypoxia and serum deprivation via the adipor1-mediated pathway. *Cell Physiol Biochem.* (2016) 38:909–25. doi: 10.1055/s-0036-15944304

43. Jiang W, Xu J. Immune modulation by mesenchymal stem cells. *Cell Proif.* (2020) 53:e12712. doi: 10.1111/cpr.12712

44. Li X, Shang B, Li Y-N, Shi Y, Shao C. IFNγ and TNFα synergistically induce apoptosis of mesenchymal stem/stromal cells via the induction of nitric oxide. *Stem Cell Res Ther.* (2019) 10:18. doi: 10.1186/s13287-018-1102-z

45. Kamali Simsek N, Benian A, Sevgin K, Ergun Y, Goksever Celik H, Karahuseyinoglu S, et al. MicroRNA analysis of human decidua mesenchymal stromal cells from preeclampsia patients. *PLoS One.* (2021) 15:129–9. doi: 10.1371/journal.pone.0261904

46. Soliman H, Theret M, Scott W, Hill L, Underhill TM, Hinz B, et al. Multipotent stromal cells: one name, multiple identities. *Stem Cell Res Ther.* (2016) 2016:9156731. doi: 10.1155/2016/9156731

47. Xiao H, Maeng YS, Jung J, Kim TW. Influence of progesterone on the expression of microRNAs in decidua-derived mesenchymal stem cells from patients with pre-eclampsia. *J Biomed Sci.* (2021) 27:64. doi: 10.1186/s12929-021-00801-3

48. Bauer M, Bauer I. Heme oxygenase-1: redox regulation and role in the hepatic response to oxidative stress. *Antioxid Redox Signal.* (2002) 4:749–58. doi: 10.1089/109004602760598891

49. Haines DD, LeBl, Teissier P, Bak I, Tosaki A. Role of haeme oxygenase-1 in resolution of oxidative stress-related pathologies: focus on cardiovascular, lung, neurological and kidney disorders. *Acta Physiol.* (2012) 204:487–501. doi: 10.1111/j.1748-1716.2011.02387.x

50. Maamoun H, Benamer T, Pintus G, Munusamy S, Agouni A, Crosstalk between oxidative stress and endoplasmic reticulum (ER) stress in endothelial dysfunction and aberrant angiogenesis associated with diabetes: a focus on the protective roles of heme oxygenase (HO-1). *Front Physiol.* (2019) 10:70. doi: 10.3389/fphys.2019.00070

51. Ryter SW. Heme oxygenase-1/carbon monoxide as modulators of autophagy and inflammation. *Arch Biochem Biophys.* (2019) 678:108186. doi: 10.1016/j.abb.2019.108186
survival in early-stage non-small cell lung cancer.

Cancer Res. (2013) 73:1180-9. doi: 10.1158/0008-5472.CAN-12-2850

12-2850

lung cancer cells.

Cancer Res. (2020) 77:188-99. doi: 10.1158/0008-5472.CAN-19-3795

11.031

of mesenchymal stem cells by targeting BMI-1.

doi: 10.1002/jcp.29069

Autophagy maintains the metabolism and function of young and old stem cells.

Adv Exp Med Biol. (2016) 887:780ñ96. doi: 10.1007/978-3-319-45727-6_7

80. Wang Y , Fan H, Zhao G, Liu D, Du L, Wang Z, et al. MiR-16 inhibits the proliferation and angiogenesis-regulating potential of mesenchymal stem cells in severe pre-eclampsia. FEBS J. (2012) 279:4510ñ24. doi: 10.1111/febs.12037

84. Mo Y , Sun Y-Y , Liu K-Y. Autophagy and inflammation in ischemic stroke. Curr Opin Cell Biol. (2015) 33:95ñ101. doi: 10.1016/j.ceb.2015.01.002

87. Zhang J, Li M, Li Z, Shi J, Zhang Y , Deng X, et al. Deletion of the type 2 renin-angiotensin system. J Cell Physiol. (2019) 234:2341-51. doi: 10.1002/jcp.26138

91. Chu Y , Chen W, Peng W, Liu Y , Li X, Bai C. Bone marrow-derived mesenchymal stem cell exosomes-mediated autophagy promotes the survival of trophoblasts under hypoxia through mTOR pathway by the downregulation of EZH2. Front Cell Dev Biol. (2020) 8:548582. doi: 10.3389/fcel.2020.548582

95. Xue H, Xu Y, Wang S, Wu Z-Y, Li X-Y, Zhang Y-H, et al. Sevoflurane post-conditioning alleviates neural rat hypoxic-ischemic cerebral injury via EZH2-regulated autophagy. Drug Design, Dev Ther. (2019) 13:1691-706. doi: 10.2147/DDDT.S197325

96. Marchi S, Bittiumerix M, Missiosi S, Morganti C, Paternani S, Shabu L, et al. Endothelial reticulin-medchondria communication through Cat(s) signaling: the importance of mitochondria-associated membranes (MAMs). Adv Exp Med Biol. (2017) 997:49ñ67. doi: 10.1007/978-981-10-4567-7_4

97. Patron M, Raffaello A, Granato V, Tosatto A, Merli G, De Stefani D, et al. The mitochondrial calcium uniporter (MCU): molecular identity and physiological roles. J Biol Chem. (2013) 288:10570ñ8. doi: 10.1074/jbc.R112.420752

98. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. (2009) 324:1029ñ33. doi: 10.1126/science.1160809

99. Zengellger ZK, Rajakumar A, Hunter JT, Salabuddin S, Rana S, Stillman IE, et al. Trophoblast mitochondrial function is impaired in preeclampsia and correlates negatively with the expression of soluble fms-like tyrosine kinase 1. Pregnancy Hypertens. (2016) 6:313ñ9. doi: 10.1016/j.preghy.2016.06.004

100. Wang L, Xu X, Kang L, Xiang W. Bone marrow mesenchymal stem cells attenuate mitochondria damage induced by hypoxia in mouse trophoblasts. Placenta. (2014) 35:1057ñ63. doi: 10.1016/j.placenta.2014.02.008

101. Seok J, Jun S, Cho J, Park S, Lee JO, Kim GJ. Human placenta-derived mesenchymal stem cells induce trophoblast invasion via dynamic effects on mitochondrial function. J Cell Physiol. (2021) 236:678ñ90. doi: 10.1002/jcp.30330

102. LeBluè VS, O’Connell JT, Gonzalez Herrera KN, Wilkman H, Pantel K, Haigs MC, et al. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. (2014) 16:992ñ1003. doi: 10.1038/ncllb03093

103. Mort K, Uchida T, Toshiie T, Mizote Y, Ishikawa F, Katsuyama M, et al. A mitochondrial ROS pathway controls matrix metalloproteinase 9 levels and invasive properties in RAS-activated cancer cells. FEBS J. (2019) 286:459-78. doi: 10.1111/febs.14671

104. Chen C-P, Chen C-Y, Wu Y-H, Chen C-Y. Oxidative stress reduces trophoblast FOXJ1 and integrin β3 expression that inhibits cell motility. Free Radic Biol Med. (2018) 124:189ñ98. doi: 10.1016/j.freeradbiomed.2018.06.006

105. Liu X, Deng Q, Luo X, Chen Y, Shan N, Qi H. Oxidative stress-induced Gadd45α inhibits trophoblast invasion and increases sFlt1/Eng secretions via p38 MAPK involving in the pathology of pre-eclampsia. J Matern Fetal Neonatal Med. (2016) 29:3776ñ85. doi: 10.3109/14767058.2016.1144744

106. Chen Y, Dorn GW II. PINK1-phosphorylated mitofusin 2 is a parkin receptor for culling damaged mitochondria. Science. (2013) 340:471ñ5. doi: 10.1126/science.1231031

107. Heeman B, Van den Haute C, Aevert S-A, Valsecchi F, Rodenburg RJ, Reuners V, et al. Depletion of PINK1 affects mitochondrial metabolism, calcium homeostasis and energy maintenance. J Cell Sci. (2011) 124:1115ñ25. doi: 10.1242/jcs.078303

108. Iriyama A, Okamoto K. PINK1/Parkin-mediated mitophagy in mammalian cells. Curr Opin Cell Biol. (2015) 33:95ñ101. doi: 10.1016/j.ceb.2015.01.002

109. Michalczyk M, Celewicz A, Celewicz M, Wozniakowska-Gondek P, Rzepka J, et al. The mitochondrial calcium uniporter (MCU): molecular identity and physiological role. J Mol Med (Berl). (2015) 93:1627ñ91. doi: 10.1007/s00109-015-2469-z

110. Fu Q, Man X, Yu M, Chu Y, Luan X, Piao H, et al. Human decidua mesenchymal stem cells regulate decidua natural killer cell function via interactions between collagen and leukocyte-associated immunoglobulin-like receptor 1. Mol Med Rep. (2017) 16:2791ñ9. doi: 10.3892/mmr.2017.9621

111. Zhang D, Lin Y, Li Y, Zhao D, Du M. Mesenchymal stem cells enhance Treg immunosuppressive function at the fetal-maternal interface. J Reprod Immunol. (2021) 148:103366. doi: 10.1016/j.jri.2021.103366

112. Hu E, Ding L, Miao H, Liu L, Dou H, et al. MiR-30a attenuates immunosuppressive functions of IL-1β-elicited mesenchymal stem cells via targeting TAB3. FEBS Lett. (2015) 589:3899ñ907. doi: 10.1111/febs.14726

113. Zhao G, Miao H, Li X, Chen S, Hu Y, Wang Z, et al. TGF-β3-induced miR-449 inhibits macrophage polarization via suppressing PGE2 secretion in mesenchymal stem cells. FEBS Lett. (2020) 590:1602ñ13. doi: 10.1002/1873-3468.12200

115. Shi Y, Wang L, Qi L, Liu K, Hou J, Shao C, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev. (2018) 14:493ñ507. doi: 10.1038/s41581-018-0023-5
T, et al. Affinity-enhanced multimeric VEGF (vascular endothelial growth factor) oxygenase in the regulation of vascular biology: from molecular mechanisms to therapeutic opportunities. *Antioxid Redox Signal*. (2011) 14:137–67. doi: 10.1089/ars.2010.3153

135. Warrington JP, Coleman K, Skaggs C, Hossick PA, George EM, Sec DE, et al. Heme oxygenase-1 promotes migration and β-epithelial Nav channel expression in cytotoxoblasts and ischemic placentas. *Am J Physiol*. (2014) 306:F641–6. doi: 10.1152/ajpregu.00566.2013

136. Wu D, Liu Y, Liu XX, Liu WY; Shi HR, Zhang Y, et al. Heme oxygenase-1 gene modified human placental mesenchymal stem cells promote placental angiogenesis and spinal artery remodeling by improving the balance of angiogenic factors in vitro. *Placenta*. (2020) 99:70–7. doi: 10.1016/j.placenta.2020.07.007

137. Liu Y, Shi H, Wu D, Xu G, Ma R, Liu X, et al. The protective benefit of heme oxygenase-1 gene-modified human placenta-derived mesenchymal stem cells in a N-Nitro-L-arginine mediated induced preeclampsia-like rat model possible implications for placental angiogenesis. *Stem Cells Dev*. (2021) 30:991–1002. doi: 10.1089/scd.2021.0174

138. Xiong ZH, Wei J, Lu MQ, Jin MY, Geng HL. Protective effect of human umbilical cord mesenchymal stem cell exosomes on preserving the morphology and angiogenesis of placenta in rats with preeclampsia. *Biomed Pharmacother*. (2018) 105:1240–7. doi: 10.1016/j.biopha.2018.06.032

139. Calle A, Gutiérrez-Reinoso MA, Re M, Blanco J, De la Fuente J, Monguio-Tortajada M, et al. Bovine peripheral blood MSCs chemotaxis towards inflammation and embryo implantation stimuli. *J Cell Physiol*. (2021) 236:1054–67. doi: 10.1002/jcp.29915

140. Calle A, Toribio V, Yáñez-Mó M, Ramirez MÁ. Embryonic trophoderm secretome reveals chemotactic migration and intercellular communication of deciduomatous and circulating MSCs in embryonic implantation. *Int J Mol Sci*. (2022) 23:5638. doi: 10.3390/ijms22156388

141. Li Y, Zhang D, Xu L, Dong L, Zheng J, Lin Y, et al. Cell-cell contact with proinflammatory macrophages enhances the immunotherapeutic effect of mesenchymal stem cells in two abortion models. *Cell Mol Immunol*. (2019) 16:908–20. doi: 10.1089/cmi.2019.0204-6

142. Eloupoulos N, Stagg I, Lejeune L, Pommye S, Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. *Blood*. (2005) 105:4057–65. doi: 10.1182/blood-2005-03-1004

143. Nauta AJ, Westerhuis G, Kruiselbrink AB, Lurwink EG, Willemsen R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonrejecting donor setting. *Blood*. (2006) 108:2114–20. doi: 10.1182/blood-2005-11-011650

144. Galland S, Stanenkovic I. Mesenchymal stromal cells in cancer: a review of their immunomodulatory functions and dual effects on tumor progression. *J Pathol*. (2020) 250:555–72. doi: 10.1002/path.5357

145. Sedeghi B, Moretti G, Arnborg F, Sæerne E, Kohein B, Catar A, et al. Preclinical toxicity evaluation of clinical grade placenta-derived decidedica cells. *Front Immunol*. (2019) 10:2685. doi: 10.3389/fimmu.2019.02685

146. Tan SJO, Florianio JP, Nicastro L, Emanuelli C, Catapano F. Novel applications of mesenchymal stem cell-derived exosomes for myocardial infarction therapies. *Biomech Model Mechanobiol*. (2020) 19:707. doi: 10.1007/s102370050707

147. Ji L, Zhang L, Li Y, Guo L, Cao N, Bai Z, et al. MRD-136 contributes to preeclampsia through its effects on apoptosis and angiogenesis of mesenchymal stem cells. *Placenta*. (2017) 50:102–9. doi: 10.1016/j.placenta.2017.01.012

148. Liu L, Wang Y, Fan H, Zhao X, Liu D, Hu Y, et al. MicroRNA-181a regulates local immune balance by inhibiting proliferation and immunosuppressive properties of mesenchymal stem cells. *Stem Cells*. (2020) 38:1756–70. doi: 10.1002/stem.1156

149. Cui J, Chen X, Lin S, Li L, Fan J, Hou H, et al. MR-D1-containing extracellular vesicles bind to BRD4 and enhance proliferation and migration of trophoblasts in placemals. *Stem Cell Res Ther*. (2020) 11:1–15. doi: 10.1186/s13287-020-01720-9

150. Yang Z, Shan N, Deng Q, Wang Y, Hou Y, Mei J, et al. Extracellular vesicle-derived microRNA-18b ameliorates preeclampsia by enhancing trophoblast proliferation and migration via Notch2/TIM3/mTORC1 axis. *J Cell Mol Med*. (2021) 25:4583–95. doi: 10.1111/cemm.13624

151. Fu L, Liu Y, Zhang D, Xie J, Guan H, Shang T. Beneficial effect of human umbilical cord-derived mesenchymal stem cells on an endotoxin-induced rat model of preeclampsia. *Exp Ther Med*. (2015) 10:1851–6. doi: 10.3892/etm.2015.2742

152. Taglauer ES, Fernandez-Gonzalez A, Willis GR, Reis M, Yeung V, Liu X, et al. Mesenchymal stem cell-derived extracellular vesicle therapy prevents preeclampsic physiology through intrauterine immunomodulation. *Biol Reprod*. (2021) 104:457–67. doi: 10.1093/biolre/ioaa198

153. Nuzzo AM, Moretti M, Melé P, Todros T, Tava C, Rolfo, A. Effect of placenta-derived mesenchymal stromal cells conditioned media on an LPS-induced mouse model of preeclampsia. *Int J Mol Sci*. (2022) 23:1674. doi: 10.3390/ijms23061674

154. Hwang S, Jeong M, Kim J, Lee J, Bae Y, Kang S, et al. Mesenchymal stem cells conditioned media on an LPS-induced mouse model of preeclampsia. *Sci Rep*. (2020) 10:15542. doi: 10.1038/s41598-020-75159-3